[go: up one dir, main page]

HUE050171T2 - Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során - Google Patents

Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során

Info

Publication number
HUE050171T2
HUE050171T2 HUE16164203A HUE16164203A HUE050171T2 HU E050171 T2 HUE050171 T2 HU E050171T2 HU E16164203 A HUE16164203 A HU E16164203A HU E16164203 A HUE16164203 A HU E16164203A HU E050171 T2 HUE050171 T2 HU E050171T2
Authority
HU
Hungary
Prior art keywords
protein
affinity chromatography
reducing
leaching during
leaching
Prior art date
Application number
HUE16164203A
Other languages
English (en)
Inventor
Robert L Fahrner
Amy Laverdiere
Paul J Mcdonald
Rhona M O'leary
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34193088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE050171(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HUE050171T2 publication Critical patent/HUE050171T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
HUE16164203A 2003-07-28 2004-06-24 Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során HUE050171T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49050003P 2003-07-28 2003-07-28

Publications (1)

Publication Number Publication Date
HUE050171T2 true HUE050171T2 (hu) 2020-11-30

Family

ID=34193088

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16164203A HUE050171T2 (hu) 2003-07-28 2004-06-24 Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
HUE04777121A HUE029951T2 (hu) 2003-07-28 2004-06-24 Protein-A-kioldódás csökkentése protein-A affinitás kromatográfia során

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE04777121A HUE029951T2 (hu) 2003-07-28 2004-06-24 Protein-A-kioldódás csökkentése protein-A affinitás kromatográfia során

Country Status (14)

Country Link
US (2) US7485704B2 (hu)
EP (3) EP3722309A1 (hu)
JP (1) JP4599355B2 (hu)
AU (1) AU2004265253B2 (hu)
CA (1) CA2531595C (hu)
DK (2) DK1648940T3 (hu)
ES (1) ES2786568T3 (hu)
HR (1) HRP20200589T1 (hu)
HU (2) HUE050171T2 (hu)
LT (1) LT3095793T (hu)
PL (2) PL3095793T3 (hu)
PT (1) PT3095793T (hu)
SI (2) SI1648940T1 (hu)
WO (1) WO2005016968A2 (hu)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
HUE050171T2 (hu) 2003-07-28 2020-11-30 Genentech Inc Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
WO2005037869A2 (en) * 2003-10-15 2005-04-28 Applera Corporation Method of reducing leachate from protein a affinity media
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7483344B2 (en) 2005-02-14 2009-01-27 Quantum Corporation Compact picker systems and methods for automated storage libraries
RU2404806C2 (ru) * 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
WO2006110292A2 (en) * 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
NZ577933A (en) * 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
WO2009009523A2 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2209498A2 (en) * 2007-10-03 2010-07-28 Cornell University Treatment of proliferative disorders using antibodies to psma
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
MX2010011955A (es) * 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20110105725A1 (en) * 2008-05-15 2011-05-05 Novo Nordisk A/S Antibody purification process
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
MX2011001696A (es) * 2008-08-14 2011-03-25 Merck Sharp & Dohme Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a.
US8338577B2 (en) * 2008-09-15 2012-12-25 Emd Millipore Corporation Methods for quantifying protein leakage from protein based affinity chromatography resins
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
SG195555A1 (en) † 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US20120141497A1 (en) 2009-03-11 2012-06-07 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
AU2010262836B2 (en) 2009-06-17 2015-05-28 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011015920A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant trastuzumab
PE20121530A1 (es) * 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20130116413A1 (en) * 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
EP2695889A1 (en) * 2009-12-29 2014-02-12 Dr. Reddy's Laboratories Limited Protein purification by ion exchange
WO2011153243A2 (en) * 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP5997176B2 (ja) 2010-12-21 2016-09-28 ザ ユニバーシティ オブ ウエスタン オンタリオＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｗｅｓｔｅｒｎ Ｏｎｔａｒｉｏ プロテインａの新規アルカリ抵抗性変異体及びアフィニティークロマトグラフィーにおけるその使用
KR101461772B1 (ko) 2010-12-21 2014-12-03 제이에스알 가부시끼가이샤 친화성 크로마토그래피용 담체 및 면역 글로불린을 단리하는 방법
PL4241849T3 (pl) 2011-10-14 2025-01-13 F. Hoffmann-La Roche Ag Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2
KR102080535B1 (ko) 2011-11-23 2020-02-24 메디뮨 엘엘씨 Her3에 특이적인 결합 분자 및 이의 용도
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
US20150218208A1 (en) 2012-08-27 2015-08-06 Asahi Kasei Medical Co., Ltd. Method for purifying antibody by temperature-responsive chromatography
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
NZ751877A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
AU2014265624B2 (en) 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
MX2016000666A (es) 2013-07-15 2017-02-15 Univ North Carolina State Ligandos peptidicos resistentes a proteasa.
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
DK3041857T3 (da) * 2013-09-04 2019-07-22 Emd Millipore Corp Protein a-kromatografi
WO2015035180A1 (en) * 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
ES2784749T3 (es) 2014-03-10 2020-09-30 Richter Gedeon Nyrt Purificación de inmunoglobulina con el uso de etapas de limpieza previa
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
EP3169801A1 (en) 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP6851109B2 (ja) * 2016-06-16 2021-03-31 Jsr株式会社 抗体を精製する方法及び担体を洗浄する方法
JP2019532999A (ja) 2016-11-04 2019-11-14 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳がんの治療
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
HUE052551T2 (hu) 2017-01-17 2021-05-28 Genentech Inc Szubkután HER2 antitest készítmények
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
WO2020206138A1 (en) 2019-04-02 2020-10-08 Bondwell Technologies Inc. Functionalized ubx protein materials for enhanced purification of antibodies
CA3151959A1 (en) * 2019-10-01 2021-04-08 James Ronald Peyser Determination of protein concentration in a fluid
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
KR20230074799A (ko) 2020-10-01 2023-05-31 이뮤니컴 인코포레이티드 리간드의 침출 감소
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4983722A (en) 1988-06-08 1991-01-08 Miles Inc. Removal of protein A from antibody preparations
ATE113846T1 (de) 1988-06-21 1994-11-15 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
AU2498192A (en) 1991-08-14 1993-03-16 Genentech Inc. Immunoglobulin variants for specific fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0656789B1 (en) 1992-08-21 1997-12-17 Genentech, Inc. Method for treating a lfa-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
DE69501817T2 (de) 1994-01-18 1998-09-10 Genentech Inc Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5686070A (en) 1994-03-03 1997-11-11 Genentech, Inc. Methods for treating bacterial pneumonia
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
AU686415B2 (en) 1994-07-13 1998-02-05 Sca Hygiene Paper Ab Method of producing a nonwoven material and nonwoven material produced according to the method
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
IL125255A (en) 1996-01-23 2002-02-10 Genentech Inc Anti-cd18 antibodies for treating stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
NO304183B1 (no) * 1996-11-22 1998-11-09 Nyfotek As FremgangsmÕte for fremstilling av heksagonal faujasitt med lavt forbruk av organisk tilsetningsstoff, samt anvendelse av denne som katalysator ved alkylering
ATE371673T1 (de) 1996-11-27 2007-09-15 Genentech Inc Affinitätsreinigung von polypeptiden an einer protein a-matrix
DE69729209T2 (de) 1996-11-27 2005-05-19 Genentech, Inc., South San Francisco Humanisierte anti-koerper gegen cd11a
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
EP1860187B1 (en) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
ES2527915T3 (es) 1998-06-09 2015-02-02 Csl Behring Ag Producto de inmunoglobulina G (IgG) líquido
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
CN101518653B (zh) 1999-06-25 2015-08-19 基因技术股份有限公司 使用抗ErbB抗体-类美坦素偶联物的治疗方法
EP1226177B1 (en) 1999-10-29 2008-07-09 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
DE10155984A1 (de) 2001-11-15 2003-05-28 Boehringer Ingelheim Pharma Verfahren zur Reduktion des Liganden-leakage von Affinitätschromatographie-Matrices
EP1472275B1 (en) * 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
EP1601697B1 (en) 2003-02-28 2007-05-30 Lonza Biologics plc Antibody purification by Protein A and ion exchange chromatography
HUE050171T2 (hu) 2003-07-28 2020-11-30 Genentech Inc Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
WO2015198451A1 (ja) 2014-06-26 2015-12-30 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Also Published As

Publication number Publication date
DK3095793T3 (da) 2020-05-25
HUE029951T2 (hu) 2017-04-28
ES2786568T3 (es) 2020-10-13
US7485704B2 (en) 2009-02-03
EP1648940B1 (en) 2016-04-27
EP3095793A1 (en) 2016-11-23
WO2005016968A2 (en) 2005-02-24
HRP20200589T1 (hr) 2020-07-10
US20090099344A1 (en) 2009-04-16
SI1648940T1 (sl) 2016-08-31
EP3095793B1 (en) 2020-03-25
AU2004265253B2 (en) 2011-09-01
US7807799B2 (en) 2010-10-05
SI3095793T1 (sl) 2020-07-31
WO2005016968A3 (en) 2005-04-21
AU2004265253A1 (en) 2005-02-24
PT3095793T (pt) 2020-05-04
CA2531595C (en) 2015-12-08
PL1648940T3 (pl) 2016-12-30
PL3095793T3 (pl) 2020-09-07
DK1648940T3 (en) 2016-08-15
EP1648940A2 (en) 2006-04-26
EP3722309A1 (en) 2020-10-14
CA2531595A1 (en) 2005-02-24
JP2007526897A (ja) 2007-09-20
US20050038231A1 (en) 2005-02-17
JP4599355B2 (ja) 2010-12-15
LT3095793T (lt) 2020-07-10

Similar Documents

Publication Publication Date Title
HUE050171T2 (hu) Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
EP1693448A4 (en) DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION
TWI318229B (en) Dyes having adapted affinity
HK1080089A1 (zh) 鼠李糖結合蛋白
GB0213760D0 (en) A fusion protein
GB0201808D0 (en) Protein
PL376318A1 (en) Protein modification
AU2003278718A8 (en) Stars-a muscle-specification-binding protein
GB0204735D0 (en) Protein
GB0202748D0 (en) Protein
GB0221470D0 (en) Protein fractionation methods for proteomics
GB0228311D0 (en) A new protein
GB0230023D0 (en) A new protein
GB0316789D0 (en) Protein assembly
GB0216987D0 (en) Xylanase binding proteins
GB0316380D0 (en) Control interface
GB0202666D0 (en) Protein
GB0204739D0 (en) Protein
GB0207471D0 (en) Protein
GB0202669D0 (en) Protein
GB0207009D0 (en) Protein
GB0206867D0 (en) Protein
GB0205811D0 (en) Protein
GB0205268D0 (en) Protein
GB0205266D0 (en) Protein